Contact us
Please fill out the details below and we will get back to you shortly.
Thank you!
We will be contacting you soon..
Close
We will be contacting you soon..
Oops! Something went wrong while submitting the form.
Portal Instruments is pleased to be showcasing its latest drug delivery platform at the LSI conference in California next week. CEO Patrick Anquetil will be available for personalized demonstrations and in-depth discussions about the technology's benefits and potential impact.
Portal Instruments will be showcasing its newest drug delivery platform at the prestigious Life Science Intelligence (LSI) conference in California next week. The company plans to showcase its latest injector platform, representing a significant advancement in reusable injectors. CEO Patrick Anquetil will be available for personalized demonstrations and in-depth discussions about the technology's benefits and potential impact on the industry. This appearance at LSI marks an important milestone for Portal as it continues to expand its market presence and forge strategic partnerships within the healthcare ecosystem. Industry experts and potential investors are encouraged to schedule meetings with the Portal team to explore collaboration opportunities and witness firsthand how their innovations are addressing critical challenges in medical delivery systems.
Portal Instruments today announced that it will further expand its partnership with Gerresheimer, an innovative system and solution provider and a global partner for the pharma, biotech and cosmetic industries, to commercialize the Prime NEXUS™ reusable, connected autoinjector platform.
March 23, 2021 - Cambridge, MA The Sumaira Foundation for NMO (TSF) and Portal Instruments are pleased to announce their partnership. Portal Instruments and TSF share a joint vision of creating a better experience and improved treatment options for patients diagnosed with NMOSD.
June 30, 2021 - The National Transgender Discrimination Survey Report on Health and Health Care recorded at least 80% of transgender people have either taken gender-affirming hormone therapy (GAHT) or want to take GAHT at some point.¹
Please fill out the details below and we will get back to you shortly.